Board of Directors
The Evox Board of Directors is comprised of highly accomplished advisors who each contribute significant expertise in their respective fields. They provide support and guidance to the management team of Evox in achieving its bold vision to positively impact human health by creating novel exosome-based biotherapeutics.
Per Lundin
Chief Executive Officer
Per Lundin is a serial entrepreneur who serves as Co-Founder & Chief Executive Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune ... Read more
Martin Andrews
Non-Executive Chairman
Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.
Evan Caplan
Non-Executive Director
Evan is a Principal on the private investment team at OrbiMed, a leading healthcare investment firm.
Wallace Wallace
Non-Executive Director
Wallace is part of the Independent Investments team at Oxford Science Enterprises, supporting portfolio companies beyond the venture-building phase. She previously invested at M Ventures and began her career in Accenture’s strategy group. Wallace holds a BSc in Genetics from the University of York and an MPhil in Bioscience Enterprise from the University of Cambridge.
Laura Feinleib
Non-Executive Director
Laura is a Vice President at Redmile Group, specialising in biotechnology venture investing. She brings experience in investment banking, biomedical engineering and optical technology development.
Sarah Gordon Wild
Non-Executive Director
Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore and Redx.
Per Lundin
Per Lundin is a serial entrepreneur who serves as Co-Founder & Chief Executive Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, which was ultimately acquired in PE-led trade sale. Over the last two decades, Per has been involved in the formation of five biotech companies developing products based on technologies ranging from cell therapies and exosomes to peptide-based drugs and non-viral delivery systems. He currently serves as board director of Breakthrough T1D International and Breakthrough T1D UK, the leading non-profit funder of research to cure, treat and prevent type 1 diabetes. He is a qualified European Patent Attorney with extensive business development and licensing experience; Per earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.
Martin Andrews
Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.
Evan Caplan
Evan is a Principal on the private investment team at OrbiMed, a leading healthcare investment firm.
Wallace Wallace
Wallace is part of the Independent Investments team at Oxford Science Enterprises, supporting portfolio companies beyond the venture-building phase. She previously invested at M Ventures and began her career in Accenture’s strategy group. Wallace holds a BSc in Genetics from the University of York and an MPhil in Bioscience Enterprise from the University of Cambridge.
Laura Feinleib
Laura is a Vice President at Redmile Group, specialising in biotechnology venture investing. She brings experience in investment banking, biomedical engineering and optical technology development.
Sarah Gordon Wild
Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore and Redx.
Scientific Advisory Board
Michael Benatar, MBChB, MS, DPhil
Professor of Neurology and the Walter Bradley Chair in ALS Research at the University of Miami Miller School of Medicine. A trailblazer in pre-symptomatic ALS research, Professor Benatar has led international consortia to discover early biomarkers and develop preventative strategies for amyotrophic lateral sclerosis.
Sarah Tabrizi, MD, PhD, FRS, FMedSci
Professor of Neurology at University College London, Director of the UCL Huntington’s Disease Centre, and Group Leader at the UK Dementia Research Institute. Professor Tabrizi spearheaded the first-in-human gene-lowering trials for Huntington’s disease, identifying key biomarkers and translational pathways for neurodegeneration.
Fyodor Urnov, PhD
Professor of Molecular Therapeutics at the University of California, Berkeley, and Director at the Innovative Genomics Institute. A pioneer in genome editing, Professor Urnov co-developed foundational CRISPR/Cas tools and, as a co-founder of the CRISPR Cures centre, helped shepherd the development of a bespoke CRISPR base-editing therapy for “Baby KJ”, the first-ever personalized in vivo gene ... Read more
Robert S. Langer, ScD
Institute Professor in the Departments of Chemical and Biomedical Engineering at MIT, and faculty member of the Harvard–MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research. A pioneer in controlled drug delivery, Langer holds over 1,400 patents and has authored over 1,600 papers. He advises Evox on brain and ... Read more
Matthew Wood, FMedSci
Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford, and Director of the Laboratory of RNA Biology and Neuromuscular Disease. He launched the field of exosome therapeutics by bioengineering exosomes for RNA delivery in the brain, demonstrating their potential as natural nanocarriers for CNS applications
Samir El Andaloussi, PhD
Professor of Biomolecular Medicine and Advanced Therapy at Karolinska Institutet, where he leads the exosome research group within the Department of Laboratory Medicine Karolinska Institutet. A pioneer in extracellular vesicle–based drug delivery, Professor El Andaloussi has characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases
Michael Benatar, MBChB, MS, DPhil
Professor of Neurology and the Walter Bradley Chair in ALS Research at the University of Miami Miller School of Medicine. A trailblazer in pre-symptomatic ALS research, Professor Benatar has led international consortia to discover early biomarkers and develop preventative strategies for amyotrophic lateral sclerosis.
Sarah Tabrizi, MD, PhD, FRS, FMedSci
Professor of Neurology at University College London, Director of the UCL Huntington’s Disease Centre, and Group Leader at the UK Dementia Research Institute. Professor Tabrizi spearheaded the first-in-human gene-lowering trials for Huntington’s disease, identifying key biomarkers and translational pathways for neurodegeneration.
Fyodor Urnov, PhD
Professor of Molecular Therapeutics at the University of California, Berkeley, and Director at the Innovative Genomics Institute. A pioneer in genome editing, Professor Urnov co-developed foundational CRISPR/Cas tools and, as a co-founder of the CRISPR Cures centre, helped shepherd the development of a bespoke CRISPR base-editing therapy for “Baby KJ”, the first-ever personalized in vivo gene editing treatment.
Robert S. Langer, ScD
Institute Professor in the Departments of Chemical and Biomedical Engineering at MIT, and faculty member of the Harvard–MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research. A pioneer in controlled drug delivery, Langer holds over 1,400 patents and has authored over 1,600 papers. He advises Evox on brain and CNS delivery.
Matthew Wood, FMedSci
Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford, and Director of the Laboratory of RNA Biology and Neuromuscular Disease. He launched the field of exosome therapeutics by bioengineering exosomes for RNA delivery in the brain, demonstrating their potential as natural nanocarriers for CNS applications
Samir El Andaloussi, PhD
Professor of Biomolecular Medicine and Advanced Therapy at Karolinska Institutet, where he leads the exosome research group within the Department of Laboratory Medicine Karolinska Institutet. A pioneer in extracellular vesicle–based drug delivery, Professor El Andaloussi has characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases